News & Views
Easier Access to Platform for COVID-19-related Development
May 06 2020 Read 718 Times
Special licensing terms have enabled faster access to Horizon Discovery’s cGMP-compliant CHOSOURCE™ platform for the development or production of therapeutic proteins, diagnostic assay components or vaccines relating to COVID-19.
The platform includes a gene-edited Glutamine Synthetase ('GS') knockout Chinese Hamster Ovary (CHO) K1 cell line, a well-established GS expression system recognised in the industry and by regulators as suitable for high yield biomanufacturing.
Jesús Zurdo, Global Head Bioprocessing, Horizon Discovery said: “The current coronavirus crisis is highlighting existing shortcomings in the development of much-needed therapeutics. Horizon Discovery is fully committed to help innovators in their efforts to develop new solutions to tackle the COVID-19 pandemic. We are providing immediate access to our state-of-the-art bioproduction platform under very favorable terms to facilitate such efforts.”
Terry Pizzie, CEO, Horizon Discovery said: “We are committed to providing flexible, royalty-free access licensing terms and solutions that streamline development and production processes. Building upon more than a decade of experience in cell line engineering, we developed our CHOSOURCE cell line and now support a growing number of pharmaceutical companies in bioproduction. We are doing all that we can to support the fight against COVID-19 and hope that offering rapid access to our CHOSOURCE platform will help to accelerate the development and validation of new therapies to combat the pandemic.”
More information online
In This Edition Articles - Expanding the Boundaries of Light Scattering for Macromolecules - Electrostatic Charges and Their Effects on Weighing - How the world’s most advanced analytical...
View all digital editions
Mar 03 2021 Guanghzou, China
Mar 08 2021 Virtual Event
Mar 22 2021 Digital event
Apr 14 2021 Tokyo, Japan
Apr 20 2021 Virtual event